Rheumatology Therapeutics Market: By Drug Class (Disease Modifying Anti Rheumatic Drugs (Synthetic, Biologic), Non Steroidal Anti Inflammatory Drugs (NSAIDs), Corticosteroids, Others), By Disorder (Rheumatoid Arthritis, Gout, Ankylosing Spondylitis, Osteo Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Rheumatology Therapeutics Market size was estimated at USD 24,568.4 million in 2022 and is poised to grow at a significant CAGR of 4.2% from 2023-2029. Rheumatology is the branch of medicine devoted to diagnosis and treatment of rheumatic diseases. Rheumatology diseases mainly affect the connecting and supporting parts of the body such as ligaments, joints, muscles, tendons and rarely some organs of the body.There are more than 100 types of rheumatic diseases are present but more common are psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis and others. Rheumatology diseases can be caused by various factors such as change in lifestyle, aging, unhealthy food and even genetic factors. The treatment is generally given with disease modifying anti rheumatic drugs and other drugs may be used to decrease the symptoms. The market is highly competitive due to the presence of the strong market players involving in development of new rheumatology therapeutics. Companies are developing the novel drugs and expanding the therapeutic applications of existing drugs.

For instance, in January 2016, Novartis AG has got two U.S. Food and Drug Administration approvals for its County to treat ankylosing spondylitis and psoriatic arthritis in U.S. in May 2017, Sanofi S.A. has got U.S. Food and Drug Administration approval for its kevazara (sarilumab) to treat active rheumatoid arthritis. Furthermore, companies also focusing on inorganic growth through acquisitions and mergers. For instance, in April 2016, Bristol Myers Squib acquired the Padlock Therapeutics Inc. along with the pipeline of rheumatoid arthritis and autoimmune drug pipeline to strengthen their market position.

Rheumatology Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Rheumatology Therapeutics Market Dynamics

Continuous growth in aging population, rise in prevalence of the diseases such as rheumatoid arthritis, ankylosing spondylitis and increase in R&D activities by the companies to develop new rheumatology therapeutics projected as primary drivers for the global rheumatology therapeutics market. In addition, rise in awareness related to symptoms and treatment of rheumatological disorders coupled with the recent product launches are expected to bolster the market growth over the forecast period. However, availability of the biosimilars, and patent expiry of some drugs is expected to hamper the global rheumatology therapeutics market during the coming years.

Rheumatology Therapeutics Market Segmentation

By Drug Class
  • Disease Modifying Anti Rheumatic Drugs
    • Synthetic
    • Biologic
  • Non Steroidal Anti Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Others
By Disorder
  • Rheumatoid Arthritis
  • Gout
  • Ankylosing Spondylitis
  • Osteo Arthritis
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Topical
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The rheumatology therapeutics market size was valued at USD 24,568.4 million in 2022.

The key segments covered in the Rheumatology therapeutics market are technology, components, application, and end-users.

The Rheumatology therapeutics market key players AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), Merck & Co. (U.S.), Amgen, Inc. (U.S.), Janssen Biotech, Inc. (Johnson & Johnson), Novartis AG (Switzerland), Genentech, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical (Japan), Celgene Corporation (U.S.), Flexion Therapeutics, Inc. (U.S.)

Key Features of the Reports

  • The rheumatology therapeutics market report provides granular level information about the market size, regional market share, historic market and forecast.
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market
1.Executive Summary
2.Global Rheumatology Therapeutics Market Introduction 
2.1.Global Rheumatology Therapeutics Market  - Taxonomy
2.2.Global Rheumatology Therapeutics Market  - Definitions
2.2.1.Drug Class
2.2.2.Disorder
2.2.3.Route of Administration
2.2.4.Distribution Channel
2.2.5.Region
3.Global Rheumatology Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Rheumatology Therapeutics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Rheumatology Therapeutics Market  By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Disease Modifying Anti Rheumatic Drugs
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Non Steroidal Anti Inflammatory Drugs (NSAIDs)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Corticosteroids
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Rheumatology Therapeutics Market  By Disorder, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Rheumatoid Arthritis
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Gout
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Ankylosing Spondylitis
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Osteo Arthritis
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Rheumatology Therapeutics Market  By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Topical
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Rheumatology Therapeutics Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Rheumatology Therapeutics Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Rheumatology Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Disease Modifying Anti Rheumatic Drugs
10.1.2.Non Steroidal Anti Inflammatory Drugs (NSAIDs)
10.1.3.Corticosteroids
10.1.4.Others
10.2.  Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Rheumatoid Arthritis
10.2.2.Gout
10.2.3.Ankylosing Spondylitis
10.2.4.Osteo Arthritis
10.2.5.Others
10.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.3.3.Topical
10.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Rheumatology Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Disease Modifying Anti Rheumatic Drugs
11.1.2.Non Steroidal Anti Inflammatory Drugs (NSAIDs)
11.1.3.Corticosteroids
11.1.4.Others
11.2.  Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Rheumatoid Arthritis
11.2.2.Gout
11.2.3.Ankylosing Spondylitis
11.2.4.Osteo Arthritis
11.2.5.Others
11.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.3.3.Topical
11.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12.Asia Pacific (APAC) Rheumatology Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Disease Modifying Anti Rheumatic Drugs
12.1.2.Non Steroidal Anti Inflammatory Drugs (NSAIDs)
12.1.3.Corticosteroids
12.1.4.Others
12.2.  Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Rheumatoid Arthritis
12.2.2.Gout
12.2.3.Ankylosing Spondylitis
12.2.4.Osteo Arthritis
12.2.5.Others
12.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.3.3.Topical
12.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Rheumatology Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Disease Modifying Anti Rheumatic Drugs
13.1.2.Non Steroidal Anti Inflammatory Drugs (NSAIDs)
13.1.3.Corticosteroids
13.1.4.Others
13.2.  Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Rheumatoid Arthritis
13.2.2.Gout
13.2.3.Ankylosing Spondylitis
13.2.4.Osteo Arthritis
13.2.5.Others
13.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.3.3.Topical
13.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Rheumatology Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Disease Modifying Anti Rheumatic Drugs
14.1.2.Non Steroidal Anti Inflammatory Drugs (NSAIDs)
14.1.3.Corticosteroids
14.1.4.Others
14.2.  Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Rheumatoid Arthritis
14.2.2.Gout
14.2.3.Ankylosing Spondylitis
14.2.4.Osteo Arthritis
14.2.5.Others
14.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parenteral
14.3.3.Topical
14.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.AbbVie Inc (U.S)
15.2.2.Pfizer Inc (U.S)
15.2.3.Bristol-Myers Squibb (U.S)
15.2.4.Merck & Co (U.S)
15.2.5.Amgen Inc (U.S)
15.2.6.Janssen Biotech Inc (Johnson & Johnson)
15.2.7.Novartis AG (Switzerland)
15.2.8.Genentech Inc (U.S)
15.2.9.Sanofi S.A (France)
15.2.10.Takeda Pharmaceutical (Japan)
15.2.11.Celgene Corporation (U.S)
15.2.12.Flexion Therapeutics Inc (U.S)
16. Research Methodology 
17. Appendix and Abbreviations 
  • AbbVie Inc (U.S)
  • Pfizer Inc (U.S)
  • Bristol-Myers Squibb (U.S)
  • Merck & Co (U.S)
  • Amgen Inc (U.S)
  • Janssen Biotech Inc (Johnson & Johnson)
  • Novartis AG (Switzerland)
  • Genentech Inc (U.S)
  • Sanofi S.A (France)
  • Takeda Pharmaceutical (Japan)
  • Celgene Corporation (U.S)
  • Flexion Therapeutics Inc (U.S)

Adjacent Markets